People · Operator
Named in public records as an officer, director or promoter · active 2026–2026 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. | — | Pharmaceuticals | Series B | $40.0M | $143.6M | 2026 |
Gilbert Lynn Marks at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gilbert Lynn Marks on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| JOSEPH S. ZAKRZEWSKI | 1 | 6 |
| Sanjay Chanda | 1 | 2 |
| Patricia Lynn Martin | 1 | 1 |
| Melvin Lynn Spigelman | 1 | 1 |
| Stephanie Lynn Wong | 1 | 1 |
| Joshua Eizen | 1 | 1 |
| Kabeer S. Aziz | 1 | 1 |
| Rob S. Readnour | 1 | 1 |
| Lucy Day | 1 | 1 |
| Eric Easom | 1 | 1 |
| Margaret Lynn FitzPatrick | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.